Jun Liu
Direktor/Vorstandsmitglied bei CHANGZHOU QIANHONG BIOPHARMA CO.,LTD
Vermögen: 18 Mio $ am 30.04.2024
Profil
Jun Liu is currently a Director at Changzhou Qianhong Biopharma Co., Ltd., Zonhon Biopharma Institute, Inc., and Aucentra Therapeutics Pty Ltd.
He previously worked as a Director-Supervisory Board at Changzhou Bio-pharma Qianhong Co. Ltd.
and as a Member at Jiangsu Biological Technology Association.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.09.2022 | 18 044 733 ( 5,04% ) | 13 Mio $ | 30.04.2024 | |
| 30.09.2022 | 6 014 911 ( 0,65% ) | 4 Mio $ | 30.04.2024 |
Aktive Positionen von Jun Liu
| Unternehmen | Position | Beginn |
|---|---|---|
| CHANGZHOU QIANHONG BIOPHARMA CO.,LTD | Direktor/Vorstandsmitglied | 15.05.2015 |
| Zonhon Biopharma Institute, Inc. | Direktor/Vorstandsmitglied | 09.02.2015 |
Aucentra Therapeutics Pty Ltd.
 Aucentra Therapeutics Pty Ltd. BiotechnologyHealth Technology Aucentra Therapeutics Pty Ltd. is an Australian biotech company that develops advanced anti-cancer drugs. The private company is based in Adelaide, Australia. Established in 2017, the company focuses on breakthrough classes of drugs to address unmet medical needs for some of the most severe cancers, including leukaemia, breast cancer, colorectal cancer, glioblastoma, lung cancer, prostate cancer, and ovarian cancer. The company's pipeline consists of first-in-class or novel kinase inhibitors in pre-clinical and clinical stage development, with a particular focus on targeting cyclin dependent kinases (cdks), known for their over-expression in cancer cells. The company was founded in 2017 by Shudong Wang, and the CEO is Joe Bayer. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jun Liu
| Unternehmen | Position | Ende |
|---|---|---|
| Changzhou Bio-pharma Qianhong Co. Ltd. | Direktor/Vorstandsmitglied | - |
| Jiangsu Biological Technology Association | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CHANGZHOU QIANHONG BIOPHARMA CO.,LTD | Health Technology |
| Private Unternehmen | 4 |
|---|---|
| Jiangsu Biological Technology Association | |
| Changzhou Bio-pharma Qianhong Co. Ltd. | |
| Zonhon Biopharma Institute, Inc. | |
Aucentra Therapeutics Pty Ltd.
Aucentra Therapeutics Pty Ltd. BiotechnologyHealth Technology Aucentra Therapeutics Pty Ltd. is an Australian biotech company that develops advanced anti-cancer drugs. The private company is based in Adelaide, Australia. Established in 2017, the company focuses on breakthrough classes of drugs to address unmet medical needs for some of the most severe cancers, including leukaemia, breast cancer, colorectal cancer, glioblastoma, lung cancer, prostate cancer, and ovarian cancer. The company's pipeline consists of first-in-class or novel kinase inhibitors in pre-clinical and clinical stage development, with a particular focus on targeting cyclin dependent kinases (cdks), known for their over-expression in cancer cells. The company was founded in 2017 by Shudong Wang, and the CEO is Joe Bayer. | Health Technology |
